<DOC>
	<DOCNO>NCT01363297</DOCNO>
	<brief_summary>The Phase 1 portion study ass safety , tolerability efficacy increase dose level inotuzumab ozogamicin subject CD22-positive relapsed refractory adult acute lymphocytic leukemia ( ALL ) order select recommend phase 2 dose ( RP2D ) schedule . The Phase 2 portion study evaluate efficacy inotuzumab ozogamicin measure hematologic remission rate ( CR + CRi ) patient second later salvage status .</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Subjects CD22positive ALL either refractory disease ( i.e . disease progression response receive recent prior anticancer therapy ) , relapse disease ( i.e . response recent prior anticancer therapy subsequent relapse ) . Subjects enrol Phase 2 portion study must due receive salvage 2 later therapy . Subjects Philadelphia chromosomepositive ( Ph+ ) ALL must fail standard treatment least one tyrosine kinase inhibitor . Adequate renal hepatic function , negative pregnancy test woman childbearing potential . Subjects isolate extramedullary relapse active central nervous system ( CNS ) leukemia . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) antiCD22 immunotherapy within 4 month , active graft versus host disease ( GvHD ) study entry . Evidence history venoocclusive disease ( VOD ) sinusoidal obstruction syndrome ( SOS ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Relapsed/Refractory Acute Lymphocytic Leukemia ( ALL )</keyword>
</DOC>